Clinical trial results and treatment resistance with lamivudine in hepatitis B

Seminars in Liver Disease

Volumn 24, Issue SUPPL. 1, 2004, Pages 31-36

  Wright, Teresa L ^a,b  

^a University of California ^*  (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Clinical trials; Hepatitis B; Lamivudine; Resistance

Indexed keywords

ADEFOVIR DIPIVOXIL; HEPATITIS B(E) ANTIGEN; INTERFERON; LAMIVUDINE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL ACTIVITY; CLINICAL TRIAL; CONFERENCE PAPER; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; HEPATITIS B; HEPATITIS B VIRUS; HISTOPATHOLOGY; HUMAN; LIVER FAILURE; NONHUMAN; PATIENT SELECTION; PRIORITY JOURNAL; SEROCONVERSION; TREATMENT OUTCOME; VIROLOGY;

ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; DNA, VIRAL; DRUG RESISTANCE, VIRAL; HEPATITIS B E ANTIGENS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; PATIENT SELECTION; TREATMENT OUTCOME;

EID: 2942530859     PISSN: 02728087     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-828676     Document Type: Conference Paper

References (26)

1. Dienstag JL, Perrillo RP, Schiff ER, et al. A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med 1995;333:1657-1661
2. Dienstag JL, Schiff ER, Wright TL, et al. Lamivudine as initial treatment for chronic hepatitis B virus in the United States. N Engl J Med 1999;341:1256-1263
3. Lai CL, Chien RN, Leung NW, et al. A one-year trial of lamivudine for chronic hepatitis B. N Engl J Med 1998;339:61-68
4. Hoonkoop P, de Man RA, Niesters HG, et al. Quantitative hepatitis B virus DNA assessment by the limiting-dilution polymerase chain reaction in chronic hepatitis B patients: evidence of continuing viral suppression with longer duration and higher dose of lamivudine therapy. J Viral Hepat 1998;5:307-312
5. Lok ASF, McMahon B. Practice Guidelines Committee, American Association for the Study of Liver Diseases (AASLD). Chronic hepatitis B: update of recommendations. Hepatology 2004;39:857-867
6. Conjeevaram HS, Lok ASF. Management of chronic hepatitis B. J Hepatol 2003;38:S90-S103
7. Lok AS, Heathcote EJ, Hoofnagle JH. Management of hepatitis B: 2000 - summary of a workshop. Gastroenterology 2001;120:1828-1853
8. EASL International Consensus Conference on Hepatitis B. 13-14 September, 2002: Geneva, Switzerland. Consensus statement (short version). J Hepatol 2003;38:533-540 (review)
9. EASL International Consensus Conference on Hepatitis B. 13-14 September, 2002: Geneva, Switzerland. Consensus statement (short version). J Hepatol 2003;38:533-540 (review)
10. Gauthier J, Bourne EJ, Lutz MW, et al. Quantitation of hepatitis B viremia and emergence of YMDD variants in patients with chronic hepatitis B treated with lamivudine. J Infect Dis 1999;180:1757-1762
11. Dienstag JL, Cianciara J, Karayalcin S, et al. Durability of serologic response after lamivudine treatment of chronic hepatitis B. Hepatology 2003;37:748-755
12. Liaw Y-F, Sung JJY, Chow WC, et al. Effects of lamivudine on disease progression and development of liver cancer in advanced chronic hepatitis B: a prospective double-blind placebo-controlled clinical trial. Hepatology 2003;38:262A
13. Tassopoulos NC, Volpes R, Pastore G, et al. Efficacy of lamivudine in patients with hepatitis B e antigen-negative/ hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Hepatology 1999;29:889-896
14. Perrillo RP, Lai C-L, Liaw Y-F, et al. Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B. Hepatology 2002;36:186-194
15. Jonas MM, Kelley DA, Mizerski J, et al. Clinical trial of lamivudine in children with chronic hepatitis B. N Engl J Med 2002;346:1706-1713
16. Schalm SW, Heatcote J, Cianciara J, et al. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B virus infection: a randomised trial. Gut 2000;46:562-568
17. Schiff ER, Dienstag JL, Karayalcin S, et al. Lamivudine and 24 weeks of lamivudine/interferon combination therapy for hepatitis B e antigen-positive chronic hepatitis B in interferon nonresponders. J Hepatol 2003;38:818-826
18. Dienstag JL, Goldin RD, Heathcote EJ, et al. Histological outcome during long-term lamivudine therapy. Gastroenterology 2003;124:105-117
19. Santantonio T, Mazzola M, Iacovazzi T, et al. Long-term follow-up of patients with anti-HBe/HBV DNA-positive chronic hepatitis B treated for 12 months with lamivudine. J Hepatol 2000;32:300-306
20. Hadzyiannis SJ, Papatheodoridis GV, Dimou E, et al. Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B. Hepatology 2000;32:847-851
21. Di Marco V, Marzano A, Lampertico P, et al. The course of anti-HBe/HBV DNA positive chronic liver disease during long-term lamivudine treatment. Program and Abstracts of the 38th Annual Meeting of the European Association for the Study of the Liver; July 3-6; 2003; Geneva, Switzerland (Abstract 4141)
22. Liaw YF, Leung NWY, Chang TT, et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Gastroenterology 2000;119:172-180
23. Leung NWY, Lai CL, Chang TT, et al. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatology 2001;33:1527-1532
24. Guan R, Lai CL, Liaw YF, et al. Efficacy and safety of 5 years lamivudine treatment of Chinese patients with chronic hepatitis B. J Gastroenterol Hepatol 2001;16(suppl 1): A60
25. Chien RN, Liaw YF, Atkins M. Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B. Hepatology 1999;30:770-774
26. Lok ASF, Lai C-L, Leung N, et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 2003;125:1714-1722